Global Hydroxychloroquine market expected to fuel by the rising demand for hydroxychloroquine to curb recent COVID-19 outbreak
Global hydroxychloroquine market estimated to grow with a noteworthy rate during the forecast period, 2020-2027. It is owing to the upsurge in demand for the treatment of various diseases such as uncomplicated malaria, lupus, and rheumatoid diseases anticipated to propel the growth of the global hydroxychloroquine market in the upcoming periods. According to WHO, there were 219 million cases of malaria in 2017. The ten highest burden African countries saw an estimated 3.5 million more malaria cases in 2017 compared with the previous year. Additionally, the global demand for hydroxychloroquine has risen sharply, leading to the use of this drug to treat diseases such as lupus or rheumatoid arthritis. Recently, the US FDA issued an Emergency Use Authorization (EUA), allowing chloroquine and hydroxychloroquine to be used to treat new coronary pneumonia.
Hydroxychloroquine is a derivative of chloroquine. Its therapeutic effect is similar to that of chloroquine, but its side effects significantly reduced. Hydroxychloroquine sulfate is an FDA class C medication for pregnancy and is available for pregnant women. Furthermore, growing demand for hydroxychloroquine to treat systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis, porphyria cutanea tarda, and Q fever, Sjögren syndrome will surge the global hydroxychloroquine industry in the future time. With the rapid development of the COVID-19 epidemic, there is a huge demand for hydroxychloroquine in the USA and Europe as these regions have seen a large number of deaths.
Application Overview in the Global Hydroxychloroquine Market
Based on application, the global hydroxychloroquine market classified into COVID-19, Malaria, Rheumatoid Arthritis, Lupus Erythematosus, Porphyria Cutanea Tarda, and Others. The COVID-19, segment projected to lead the hydroxychloroquine market owing to the surge in demand for anti-malarial drug Hydroxychloroquine to treat new coronary pneumonia disease, COVID-19. Hydroxychloroquine is an analog of chloroquine that has fewer concerns about drug-drug interactions. In the previous SARS outbreak, it was reported to have anti-SARS-CoV activity in vitro. It suggests that hydroxychloroquine may be a potential pharmacological agent for the treatment of COVID-19 infection.
Malaria segment will influence due to the hydroxychloroquine is used for the treatment of complicated malaria.
Lupus Erythematosus will drive in the forecast period owing to the demand for hydroxychloroquine in the treatment of diseases like chronic discoid lupus erythematosus and systemic lupus erythematosus in adults.
End-User Overview in the Global Hydroxychloroquine Market
Based on end-user, the global hydroxychloroquine market categorized into Hospital, Pharmacy Store, Clinics, and Others. The hospital segment witnessed a higher market share in 2019 and will continue to lead the hydroxychloroquine market by 2027. It is due to surge in the covid-19 infected patients around the world along with increment in the number of hospitals by converting public building institutional centers turning into quarantine center. Additionally, the easy availability of medical equipment at the hospital will propel the hospital segment market.
Pharmacy Store will drive in the forecast period attributable to the rise in the number of infected cases from malaria and Rheumatoid Arthritis along with the huge increment in the number of pharmacy stores in the developing countries.
Regional Overview in the Global Hydroxychloroquine Market
By geography, the global hydroxychloroquine Market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America anticipated to dominating the hydroxychloroquine market by 2027. The surge in the number of COVID-19 infected populations, approval of hydroxychloroquine by FDA for treating COVID-19, and the presence of key manufacturing companies in the region, is pulling up the growth.
Europe will be the fastest-growing region in the hydroxychloroquine market during the forecast period. It is attributable to the authorization for the use of hydroxychloroquine in COVID-19 by EU administration coupled with the maximum number of death cases of COVID-19 Western Europe.
Global Hydroxychloroquine Market: Competitive Landscape
Companies such as Sanofi SA, Novartis International AG, Mylan N.V., Teva Pharmaceuticals. Ipca Laboratories, Cadila Healthcare Lt, Wallace Pharmaceuticals Ltd., and Macleods Pharmaceuticals are the key players in the Global Hydroxychloroquine Market.
Global Hydroxychloroquine Market
Report Content
1. Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. Executive Summary
4. Market Insights
4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Competitors & Product Analysis
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porter's Five forces analysis
4.7. New Investment Analysis
4.8. PESTEL Analysis
5. Global Hydroxychloroquine Market Overview
5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Application
5.2.1.1. Covid-19
5.2.1.2. Malaria
5.2.1.3. Rheumatoid Arthritis
5.2.1.4. Lupus Erythematosus
5.2.1.5. Porphyria Cutanea Tarda
5.2.1.6. Others
5.2.2. By End-Users
5.2.2.1. Hospital
5.2.2.2. Pharmacy Store
5.2.2.3. Clinics
5.2.2.4. Others
5.2.3. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. Asia Pacific
5.2.3.4. South America
5.2.3.5. Middle East & Africa
6. North America Hydroxychloroquine Market Overview
6.1. North America Hydroxychloroquine Market Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. North America Hydroxychloroquine Market Share & Forecast, 2016-2027
6.2.1. By Application
6.2.1.1. Covid-19
6.2.1.2. Malaria
6.2.1.3. Rheumatoid Arthritis
6.2.1.4. Lupus Erythematosus
6.2.1.5. Porphyria Cutanea Tarda
6.2.1.6. Others
6.2.2. By End-Users
6.2.2.1. Hospital
6.2.2.2. Pharmacy Store
6.2.2.3. Clinics
6.2.2.4. Others
6.2.3. By Country
6.2.3.1. US
6.2.3.2. Canada
6.2.3.3. Mexico
6.2.4. Price-Point Analysis
6.2.5. Manufacturer & Distributor List (Top 5)
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on North America Hydroxychloroquine Market
7. Europe Hydroxychloroquine Market Overview
7.1. Europe Hydroxychloroquine Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. Europe Hydroxychloroquine Market Share & Forecast, 2016-2027
7.2.1. By Application
7.2.1.1. Covid-19
7.2.1.2. Malaria
7.2.1.3. Rheumatoid Arthritis
7.2.1.4. Lupus Erythematosus
7.2.1.5. Porphyria Cutanea Tarda
7.2.1.6. Others
7.2.2. By End-Users
7.2.2.1. Hospital
7.2.2.2. Pharmacy Store
7.2.2.3. Clinics
7.2.2.4. Others
7.2.3. By Country
7.2.3.1. Germany
7.2.3.2. UK
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Rest of Europe
7.2.4. Price-Point Analysis
7.2.5. Manufacturer & Distributor List (Top 5)
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on Europe Hydroxychloroquine Market
8. Asia Pacific Hydroxychloroquine Market Overview
8.1. Asia Pacific Hydroxychloroquine Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific Hydroxychloroquine Market Share & Forecast, 2016-2027
8.2.1. By Application
8.2.1.1. Covid-19
8.2.1.2. Malaria
8.2.1.3. Rheumatoid Arthritis
8.2.1.4. Lupus Erythematosus
8.2.1.5. Porphyria Cutanea Tarda
8.2.1.6. Others
8.2.2. By End-Users
8.2.2.1. Hospital
8.2.2.2. Pharmacy Store
8.2.2.3. Clinics
8.2.2.4. Others
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia
8.2.3.5. Rest of Asia Pacific
8.2.4. Price-Point Analysis
8.2.5. Manufacturer & Distributor List (Top 5)
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific Hydroxychloroquine Market
9. South America Hydroxychloroquine Market Overview
9.1. South America Hydroxychloroquine Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America Hydroxychloroquine Market Share & Forecast, 2016-2027
9.2.1. By Application
9.2.1.1. Covid-19
9.2.1.2. Malaria
9.2.1.3. Rheumatoid Arthritis
9.2.1.4. Lupus Erythematosus
9.2.1.5. Porphyria Cutanea Tarda
9.2.1.6. Others
9.2.2. By End-Users
9.2.2.1. Hospital
9.2.2.2. Pharmacy Store
9.2.2.3. Clinics
9.2.2.4. Others
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Argentina
9.2.3.3. Rest of South America
9.2.4. Price-Point Analysis
9.2.5. Manufacturer & Distributor List (Top 5)
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America Hydroxychloroquine Market
10. Middle East & Africa Hydroxychloroquine Market Overview
10.1. Middle East & Africa Hydroxychloroquine Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa Hydroxychloroquine Market Share & Forecast, 2016-2027
10.2.1. By Application
10.2.1.1. Covid-19
10.2.1.2. Malaria
10.2.1.3. Rheumatoid Arthritis
10.2.1.4. Lupus Erythematosus
10.2.1.5. Porphyria Cutanea Tarda
10.2.1.6. Others
10.2.2. By End-Users
10.2.2.1. Hospital
10.2.2.2. Pharmacy Store
10.2.2.3. Clinics
10.2.2.4. Others
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
10.2.4. Price-Point Analysis
10.2.5. Manufacturer & Distributor List (Top 5)
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa Hydroxychloroquine Market
11. Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Sanofi SA
11.7.2. Novartis International AG
11.7.3. Mylan N.V.
11.7.4. Teva Pharmaceuticals
11.7.5. Ipca Laboratories
11.7.6. Cadila Healthcare Ltd
11.7.7. Wallace Pharmaceuticals Ltd.
11.7.8. Macleods Pharmaceuticals
11.7.9. Other Prominent Players